NASDAQ:CNATConatus Pharmaceuticals Stock Price, Forecast & News

$4.50

+0.08 (+1.81 %)

(As of 06/5/2020 04:00 PM ET)

Add

Compare

Today's Range

$4.44

Now: $4.50▼

$4.60

50-Day Range

$0.31

MA: $0.76▼

$4.33

52-Week Range

$0.23

Now: $4.50▼

$1.07

Volume40,543 shs

Average Volume1.28 million shs

Market Capitalization$149.27 million

P/E RatioN/A

Dividend YieldN/A

Beta1.84

Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidate includes Emricasan, an orally active caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for portal hypertension; for liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function. The company is also developing CTS-2090, an orally active inhibitor of caspase 1, which is in preclinical development stage for treating chronic diseases involving inflammasome pathways. The company has a collaboration agreement with Novartis to conduct three Phase IIb clinical trials. Conatus Pharmaceuticals Inc. was founded in 2005 and is headquartered in San Diego, California.

Beat the Market (BTM) Rank^™

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Conatus Pharmaceuticals.

3.3 Community Rank

Outperform Votes
Conatus Pharmaceuticals has received 537 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Conatus Pharmaceuticals has received 275 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Conatus Pharmaceuticals has received 66.13% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Conatus Pharmaceuticals and other stocks. Vote “Outperform” if you believe CNAT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CNAT will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Conatus Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Conatus Pharmaceuticals does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Conatus Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 11.30% of the stock of Conatus Pharmaceuticals is held by insiders.
Percentage Held by Institutions
Only 15.20% of the stock of Conatus Pharmaceuticals is held by institutions.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Conatus Pharmaceuticals is -15.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Conatus Pharmaceuticals is -15.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Conatus Pharmaceuticals has a P/B Ratio of 8.49. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

0.66 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:CNAT

Previous Symbol

CUSIPN/A

CIK1383701

Webwww.conatuspharma.com

Phone858-376-2600

Debt

Debt-to-Equity RatioN/A

Current Ratio16.28

Quick Ratio16.28

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$21.72 million

Price / Sales6.87

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.53 per share

Price / Book8.49

Profitability

EPS (Most Recent Fiscal Year)N/A

Net Income$-11,390,000.00

Net Margins-52.42%

Return on Equity-48.22%

Return on Assets-39.32%

Miscellaneous

Employees30

Outstanding Shares33,170,000

Market Cap$149.27 million

Next Earnings Date8/4/2020 (Estimated)

OptionableOptionable

Receive CNAT News and Ratings via Email

Sign-up to receive the latest news and ratings for CNAT and its competitors with MarketBeat's FREE daily newsletter.

Conatus Pharmaceuticals (NASDAQ:CNAT) Frequently Asked Questions

How has Conatus Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Conatus Pharmaceuticals' stock was trading at $0.3418 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CNAT stock has increased by 1,216.6% and is now trading at $4.50. View which stocks have been most impacted by Coronavirus.

When is Conatus Pharmaceuticals' next earnings date?

Conatus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Conatus Pharmaceuticals.

How were Conatus Pharmaceuticals' earnings last quarter?

Conatus Pharmaceuticals Inc (NASDAQ:CNAT) issued its quarterly earnings data on Friday, May, 1st. The biotechnology company reported ($0.10) earnings per share for the quarter, hitting the Zacks' consensus estimate of ($0.10). Conatus Pharmaceuticals had a negative net margin of 52.42% and a negative return on equity of 48.22%. View Conatus Pharmaceuticals' earnings history.

Has Conatus Pharmaceuticals been receiving favorable news coverage?

News headlines about CNAT stock have been trending negative on Saturday, InfoTrie reports. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Conatus Pharmaceuticals earned a coverage optimism score of -2.1 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 3.0 out of 10, indicating that recent media coverage is unlikely to have an effect on the company's share price in the next few days. View the latest news aboutConatus Pharmaceuticals.

Are investors shorting Conatus Pharmaceuticals?

Conatus Pharmaceuticals saw a decrease in short interest in May. As of May 15th, there was short interest totaling 130,700 shares, a decrease of 10.5% from the April 30th total of 146,000 shares. Based on an average daily trading volume, of 759,100 shares, the short-interest ratio is currently 0.2 days. Currently, 0.4% of the company's stock are short sold. View Conatus Pharmaceuticals' Current Options Chain.

Who are some of Conatus Pharmaceuticals' key competitors?

Some companies that are related to Conatus Pharmaceuticals include Frequency Therapeutics (FREQ), Radius Health (RDUS), Aprea Therapeutics (APRE), Athersys (ATHX), Urogen Pharma (URGN), Zafgen (ZFGN), Basilea Pharmaceutica (BPMUF), Viking Therapeutics (VKTX), Atreca (BCEL), AnaptysBio (ANAB), Crinetics Pharmaceuticals (CRNX), Corbus Pharmaceuticals (CRBP), Clovis Oncology (CLVS), VBI Vaccines (VBIV) and Emisphere Technologies (EMIS). View all competitors.

What other stocks do shareholders of Conatus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Conatus Pharmaceuticals investors own include KNOT Offshore Partners (KNOP), Trevena (TRVN), PPL (PPL), Cascadian Therapeutics (CASC), Vaxart (VXRT), Antares Pharma (ATRS), Novavax (NVAX), Dextera Surgical (DXTR), Geron (GERN) and Verastem (VSTM).

Who are Conatus Pharmaceuticals' key executives?

Conatus Pharmaceuticals' management team includes the following people:

Dr. Steven J. Mento, Co-Founder, Pres, CEO & Director (Age 67)
Dr. Keith W. Marshall MBA, Ph.D., Exec. VP, COO & CFO (Age 51)
Dr. David T. Hagerty, Exec. VP of Clinical Devel. (Age 64)
Dr. Alfred P. Spada, Co-Founder, Exec. VP of R&D and Chief Scientific Officer (Age 61)
Mr. Alan R. Engbring, Exec. Director of Investor Relations & Corp. Communications

What is Conatus Pharmaceuticals' stock symbol?

Conatus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNAT."

Who are Conatus Pharmaceuticals' major shareholders?

Conatus Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Acadian Asset Management LLC (4.07%). View institutional ownership trends for Conatus Pharmaceuticals.

Which major investors are buying Conatus Pharmaceuticals stock?

CNAT stock was bought by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC. View insider buying and selling activity for Conatus Pharmaceuticals.

How do I buy shares of Conatus Pharmaceuticals?

Shares of CNAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Conatus Pharmaceuticals' stock price today?

One share of CNAT stock can currently be purchased for approximately $4.50.

How big of a company is Conatus Pharmaceuticals?

Conatus Pharmaceuticals has a market capitalization of $149.27 million and generates $21.72 million in revenue each year. Conatus Pharmaceuticals employs 30 workers across the globe.

What is Conatus Pharmaceuticals' official website?

The official website for Conatus Pharmaceuticals is www.conatuspharma.com.

How can I contact Conatus Pharmaceuticals?

Conatus Pharmaceuticals' mailing address is 16745 W. Bernardo Dr. Suite 250, San Diego CA, 92127. The biotechnology company can be reached via phone at 858-376-2600 or via email at [email protected]

This page was last updated on 6/6/2020 by MarketBeat.com Staff